Pharmacodynamics of cyclosporine in heart and heart-lung transplant recipients: I: Blood cyclosporine concentrations and other risk factors for cardiac allograft rejection

Transplantation

Volumn 62, Issue 10, 1996, Pages 1429-1435

  Best, Nicola G ^a,b   Trull, Andrew K ^c   Tan, Keith K C ^c,d   Spiegelhalter, David J ^a   Cary, Nat ^e   Wallwork, John ^e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0029837108     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199611270-00009     Document Type: Article

References (25)

1. Lindholm A. Therapeutic monitoring of cyclosporine - an up-date. Eur J Clin Pharmacol 1991; 41: 273.
2. Carrier M, Russell DH, Cork RC, Wild J, Emery RW, Copeland JG. Analysis of risk factors for acute allograft rejection after heart transplantation. J Heart Transplant 1990; 9: 372.
3. Laufer G, Miholic J, Laczkovics A, et al. Independent risk factors predicting graft rejection in cardiac transplant recipients treated by triple drug immunosuppression. J Thorac Cardiovasc Surg 1989; 98: 1113.
4. Kahan BD, Kramer WG, Wideman C, et al. Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. In: Kahan BD, ed. Cyclosporine - pharmacologic aspects. New York: Grune & Stratton, 1987: 115.
5. Shaw LM, Bowers LD, Demer L, et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clin Chem 1987; 33: 1269.
6. Kahan BD, Shaw LM, Holt DW, Grevel J, Johnston A. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990; 36: 1510.
7. Shaw LM, Yatscoff RW, Bowers LD, et al. Canadian consensus meeting on cyclosporine monitoring: report of the Consensus Panel. Clin Chem 1990; 36: 1841.
8. White DJG. Immunosuppression for cardiac transplantation. In: Wallwork J, ed. Heart and heart-lung transplantation. London: WB Saunders, 1989.
9. Wallwork J. Cyclosporin: issues of today. Oxford: Medical Education Services, 1986.
10. Best NG, Trull AK, Tan KKC, et al. Blood cyclosporine concentrations and the short-term risk of lung rejection following heart-lung transplantation. Br J Clin Pharmacol 1992; 34: 513.
11. Billingham ME. Diagnosis of cardiac rejection by endomyocardial biopsy. Heart Transplant 1982; 1: 25.
12. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant 1990; 9: 587.
13. Liang KY, Zeger SL. Longitudinal data analysis using generalized estimating equations. Biometrika 1986; 73: 13.
14. Trull AK, Best NG, Tan KKC, et al. Blood cyclosporine concentrations but not dose correlate with acute changes in renal function following heart and heart-lung transplantation. Therap Drug Monit 1992; 14: 275.
15. Yee G, Self S, McGuire T, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporin concentration and risk of acute graft-versus-host disease after allogenic marrow transplantation. N Engl J Med 1988; 319: 65.
16. Strom TB. Immunosuppression in tissue and organ transplantation. In: Brent L, Sells RA, eds. Organ transplantation: current clinical and immunological concepts. London, Bailliere Tindall, 1989: 57.
17. Valentine H, Hunt S, Gambert P, Miller J. Impact of cyclosporine dose on log-term outcome after cardiac transplantation. Presented at The Third International Congress on Cyclosporin, Seville, April, 1994.
18. Cantarovich M, Latter D. Is there a relationship between cyclosporine A trough levels and endomyocardial biopsy score after heart transplantation? Presented at The Third International Congress on Cyclosporin, Seville, April 1994.
19. Kobashigawa J, Stevenson L, Moriguchi J, et al. Randomized study of high dose oral cyclosporine therapy for mild acute cardiac rejection. J Heart Transplant 1989; 8: 53.
20. Laufer G, Laczkovics A, Wollenek C, et al. The progression of mild acute cardiac rejection evaluated by risk factor analysis. Transplantation 1991; 51: 184.
21. Best NG. Dynamic models for post-transplant patient monitoring. (Ph.D. thesis, Department of Community Medicine, University of Cambridge, December 1993).
22. Holt DW, Johnston A, Roberts NB, Tredger JM, Trull AK. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clincal Biochemists task force. Ann Clin Biochem 1994; 31: 420.
23. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323: 1767.
24. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephrotoxicity. Kidney Int 1988; 33: 590.
25. Smith JD, Rose ML, Pomerance A, Burke M, Yacoub MH. Reduction of cellular rejection and increase in longer-term survival after heart-transplantation after HLA-DR matching. Lancet 1995; 346: 1318.